Navigation Links
Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA
Date:2/28/2011

SAN MARINO, Calif., Feb. 28, 2011 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the U.S. FDA has granted Phase 3 status for the Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek out and destroy metastatic cancer. According to Dr. Maria Gordon, Chief Medical Officer of Epeius, "What this means, in terms of clinical development, is that the Rexin-G product, with its advanced GMP manufacturing, bio-processing, and final formulation, meets rigorous FDA standards for obtaining a marketing license in the future; and that Epeius Biotech can now proceed with its strategic, diversified Phase 3 drug development program for pancreatic cancer, osteosarcoma and soft tissue sarcoma."

In addition to these high-priority programs, Rexin-G has demonstrated significant anti-tumor activity in chemotherapy-resistant breast cancer, hormone-refractory prostate cancer, ovarian cancer, squamous cell carcinoma, and certain hematologic malignancies, such as large B-cell lymphoma.

Rexin-G® was granted accelerated approval for the treatment of all chemotherapy-resistant solid malignancies in the Republic of the Philippines in 2007. In the U.S.A., Rexin-G gained Orphan Drug Designation and market protections from the FDA for pancreatic cancer in 2003, followed by Orphan Drug Status for both osteosarcoma and soft tissue sarcoma in 2008.  More recently, Epeius Biotechnologies completed a series of Phase 1 and Phase 2 clinical trials in the U.S., establishing the thresholds for bioactivity and dose-dependent efficacy for Rexin-G against a number of otherwise intractable cancers, as well as the product's overall safety over extended survival times and a notable lack of either safety issues or dose
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
2. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
5. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
6. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
10. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
11. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ ... CO ), China,s leading provider of cord blood ... storage services, today announced that the underwriters of its recent ... their over-allotment option, which will result in the issuance of ...
... NORTH BILLERICA, Mass., Dec. 29 Seahorse Bioscience, Inc., leader ... bioenergetics, announced that TheScientist magazine cited their XF96 ... A panel of scientific experts assembled by TheScientist ... the two energy pathways of the cell in a microplate, ...
... , EMERYVILLE, Calif., Dec. 29 ... of results from its study on the anti-tumor mechanism of ... International Journal of Cancer , describe the potential molecular ... BN107 on estrogen receptor negative (ER-) breast cancer cells. , ...
Cached Biology Technology:China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 3
(Date:4/20/2014)... and pancreatic cancers also promote drug-resistance and ultimately spur ... Diego School of Medicine have discovered a molecule, or ... that appears responsible for inducing tumor metastasis by enhancing ... The findings, published in the April 20, 2014 online ... to new therapeutic opportunities for reversing drug resistance in ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... Jianmin Cui was handed a puzzling clue to the structure ... five years. Scientists at the Cleveland Clinic Foundation in ... epilepsy, sudden attacks of involuntary movement or both, a syndrome ... the DNA of the 16 family members who had inherited ...
... are fostering development of a new generation of vaccines, ... potentially deadly bacteria in any future bioterrorist incident. That,s ... on medical technology to combat the anthrax threat. It ... . In the article, Dimitrios Bouzianas notes ...
... Scientists are reporting that particle size affects the toxicity ... smaller than 100 nanometers are slightly more toxic to colon ... toxic than equivalent amounts of soluble zinc, and direct particle ... study is in ACS, Chemical Research in Toxicology , ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
... for your specific applications and built on ... platform. Thousands of customer specified sequences can ... provide assistance with custom sequence design. These ... comprehensive Custom DNA Microarray Service. ...
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Microarray contains greater than 1500 known aptamer ...
... for DNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
Biology Products: